E4/DRSP Ovarian Function Inhibition Study

Inclusion Criteria: * Overtly healthy female subjects, as determined by medical history, physical examination including breast examination, gynecological examination (including cervical smear \[Pap smear\]), vital signs, ECG, echocardiogram, and laboratory tests. * Negative pregnancy test at subject screening. * Women who ovulate in the Pre-Treatment Cycle. * Willing to use a non-hormonal method of contraception (e.g. condom) during the wash-out period, Pre-Treatment Cycle and Post-Treatment Cycle. * BMI between 18.0 and 35.0 kg/m², inclusive, at time of Screening. * Able to fulfill the requirements of the protocol and have indicated a willingness to participate in the study by providing written informed consent form (ICF). Exclusion Criteria: * Irregular menstrual cycle. * Amenorrhea or abnormal uterine bleeding. * Clinically relevant abnormal laboratory result at Screening. * Clinically significant abnormalities of the uterus and/or ovaries detected by examination and/or ultrasound. * Known hypersensitivity to any of the investigational or reference product ingredients. * Intention to become pregnant during the course of the study. * Pregnancy during accurate hormonal contraceptive use in the past. * Dyslipoproteinemia requiring active treatment with antilipidemic agent. * Diabetes mellitus with vascular involvement (nephropathy, retinopathy, neuropathy, other) or diabetes mellitus of more than 20-year duration. * Any arterial hypertension. * Any condition associated with an increased risk of venous thromboembolism and/or arterial thromboembolism. * Complicated valvular heart disease. * History of pregnancy-related cardiomyopathy or moderately or severely impaired cardiac function. * Systemic lupus erythematosus. * Presence or history of migraine with aura. * Abnormal Papanicolaou (PAP) smear result. * Presence of an undiagnosed breast mass. * Current symptomatic gallbladder disease. * History of COC-related cholestasis. * Presence or history of severe hepatic disease. * Presence or history of pancreatitis if associated with hypertriglyceridemia. * Porphyria. * Presence or history of hepatocellular adenoma or malignant liver tumors. * Renal impairment. * Hyperkaliemia or presence of conditions that predispose to hyperkaliemia. * Presence or history of hormone-related malignancy. * History of non-hormone-related malignancy within 5 years before Screening. Subjects with a non-melanoma skin cancer are allowed in the study. * Use of drugs potentially triggering interactions with COCs. * History of alcohol or drug abuse. * Any prior procedure, disease or condition that could result in altered absorption, excessive accumulation, impaired metabolism, or altered excretion of the investigational product. * Uncontrolled thyroid disorders. * Have received an investigational drug within the last 2 cycles prior to start of Pre-Treatment Cycle. Subjects who participated in an oral contraceptive clinical study, using Food and Drug Administration (FDA)/European Union (EU) approved active ingredients, may start the Pre-Treatment Cycle one cycle after last medication intake of the preceding study. * Sponsor, contract research organization (CRO) or PI's site personnel directly affiliated with this study. * Is judged by the PI to be unsuitable for any reason.